Overview

A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

Status:
Terminated
Trial end date:
2014-11-17
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to find out how successfully, patients with progressive metastatic cutaneous melanoma, are able to develop an immune response to injections with the immunotherapeutic product GSK1572932A when given in combination with dacarbazine and evaluate the safety of this combination.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Dacarbazine
Imidazole